Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients With Primary IgAN

NCT07498335 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

28

Enrollment

INDUSTRY

Sponsor class

Conditions

Berger Disease
Bergers Disease
IgA Nephropathy
Immunoglobulin A Nephropathy
Primary IgAN
Nephritis IgA Type, Nephropathy IgA Type

Interventions

DRUG: Drug: Atrasentan

Sponsor

Novartis Pharmaceuticals